Maxigen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, sales was TWD 313.95 million compared to TWD 277.49 million a year ago. Net income was TWD 106.8 million compared to TWD 54.03 million a year ago. Basic earnings per share from continuing operations was TWD 1.2 compared to TWD 0.6095 a year ago. Diluted earnings per share from continuing operations was TWD 1.2 compared to TWD 0.6095 a year ago.